ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.)

ADVMのニュース

   The Best-Performing Small-Cap Stocks YTD: May 2019  2019-05-16
The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am…
   Microcaps mostly among midday movers  2019-05-16
Gainers: Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D…
   Adverum up 16% on advancement of ADVM-022 in early-stage wet AMD study  2019-05-16
Adverum Biotechnologies ( ADVM +16% ) is up on almost 20% higher volume in response to its announcement that the FDA has lifted the clinical hold on the second cohort in a Phase 1 study, OPTIC , evaluating lead gene therapy ADVM-022 (AAV.7m8-aflibercept) in patients with wet age-rel…
   The Best-Performing Small-Cap Stocks YTD: May 2019  2019-05-16
The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am…
   Microcaps mostly among midday movers  2019-05-16
Gainers: Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D…
   Adverum up 16% on advancement of ADVM-022 in early-stage wet AMD study  2019-05-16
Adverum Biotechnologies ( ADVM +16% ) is up on almost 20% higher volume in response to its announcement that the FDA has lifted the clinical hold on the second cohort in a Phase 1 study, OPTIC , evaluating lead gene therapy ADVM-022 (AAV.7m8-aflibercept) in patients with wet age-rel…

calendar